Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

The abortion drug mifepristone is pictured in in this file photo.

Phil Walter/Getty Images

A decision on whether to approve the abortion pill in Canada has once again been delayed, likely until the fall, according to the organization that represents abortion providers in Canada and the United States.

The president of the National Abortion Federation said on Tuesday that Health Canada has asked for more information from the European drug company that has applied to sell mifepristone in Canada, a request that means the federal regulator is unlikely to issue a ruling on the drug until later this year.

"Certainly, we're disappointed with the delay," Vicki Saporta told The Globe and Mail in an interview. "But I'm very optimistic that, at the end of the day, Health Canada will approve mifepristone and it will be available for Canadian women to use next year. We're making forward progress."

Story continues below advertisement

The National Abortion Federation, which represents 80 per cent of abortion providers in Canada, has been helping the drug company, Linepharma International, with its application to sell a combination pack of mifepristone and misoprostol, a second drug required to complete a medical abortion that is approved in Canada for other uses.

Ms. Saporta told The Globe last month that Health Canada had set an internal deadline of mid-January to decide on the application, which was submitted in October, 2011, and resubmitted in 2012, according to Marion Ulmann, the company's chief operating officer.

Asked about the decision being postponed, Ms. Ulmann, Linepharma's chief operating officer, said by e-mail Tuesday night ‎that the application has proceeded as expected.

"So far the registration procedure has gone uneventfully along with usual Health Canada procedures and there is no predefined date for the end of the procedure," she said.

Health Canada has an internal service standard of 300 days to issue a decision on a new drug application. However, a spokesman said processing an application can take as long as two or three years if the regulator requests more data from pharmaceutical companies.

Mifepristone is already approved in 60 countries, including the United States, Australia and most of Europe.

More than 750 days have elapsed since Linepharma resubmitted its application.

Story continues below advertisement

That is longer than Health Canada has taken to approve any other new drug in recent years, according to a Toronto professor who studies how Health Canada reviews drug applications.

Joel Lexchin, a professor in the school of health policy and management at York University, reviewed the time it took Health Canada to approve 41 new drugs in the two years leading up to March 31 of last year. The longest application took 644 days.

Mifepristone, when combined with misoprostol, is generally used to terminate a pregnancy between seven and nine weeks. NAF and other organizations that support bringing the medical abortion drug to Canada say it will make ending a pregnancy more discreet and widely available, especially in areas where services are scarce.

But opponents of the drug warn it is not safe for women, a contention NAF says is not supported by more than 20 years of medical evidence.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies